2013 Volume 23 Issue 1 Pages 168-175
In the U.S. a litigation was filed to invalidate the patents of Myriad Genetics, Inc. on BRCA1 and BRCA2, which were linked with human breast and ovarian cancers. The U.S. Court of Appeals for the Federal Circuit (CAFC) reviewed the case after it was remanded by the Supreme Court, and CAFC judged that such patents were eligible again. The Supreme Court will begin examination upon the judgment hereafter. In this thesis I reviewed the circumstances of the trial and considered its influences on the related people and sectors. I also considered the way to harmonize gene patents with society, industry and research.
